Voyager Therapeutics (VYGR) Assets (2014 - 2026)

Voyager Therapeutics has disclosed Assets across 13 years of filings, most recently posting $197.8 million for Q2 2026.

• In Q2 2026, Assets fell 38.61% year-over-year to $197.8 million; the TTM figure through Jun 2026 stood at $197.8 million (down 38.61% YoY), while the FY2025 annual figure was $252.3 million, down 35.81% from the prior year.
• Assets came in at $197.8 million for Q2 2026 at Voyager Therapeutics, down from $219.3 million in the prior quarter.
• In the past five years, Assets ranged from a high of $469.6 million in Q1 2024 to a low of $159.4 million in Q4 2022.
• Average Assets over 5 years is $300.6 million, with a median of $305.1 million recorded in 2023.
• Year-over-year, Assets jumped 120.44% in 2023 and tumbled 38.61% in 2026.
• Over 5 years, Assets stood at $159.4 million in 2022, then jumped by 120.44% to $351.3 million in 2023, then gained by 11.89% to $393.0 million in 2024, then slumped by 35.81% to $252.3 million in 2025, then slipped by 21.61% to $197.8 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $197.8 million in Q2 2026, $219.3 million in Q1 2026, and $252.3 million in Q4 2025.